Electrocardiogram-gated Computed Tomography with Coronary Angiography for Cardiac Substructure Delineation and Sparing in Patients with Mediastinal Lymphomas Treated with Radiotherapy

ConclusionsCardiac substructure delineation using E-CTA was feasible and inclusion in optimization led to modest improvements in sparing of radiosensitive cardiac substructures for some patients.
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

We present an 81-year-old male patient with high-risk non-nodal leukemic MCL, with exorbitant leukocytosis/lymphocytosis, and an unprecedented finding of a morphology mimicking adult T cell leukemia, given the presence of flower cells in peripheral blood. This is the only case of MCL and one of the few B-cell lymphomas with this atypical morphology ever reported. Relevant literature hypotheses about the origin of this morphology are discussed
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Conclusion: B-cell in BL contained somatic mutated IgHV gene and upregulated cellular microRNAs with possible pathogenetic role(s).Keywords: IgHV; somatic hypermutation; microRNA; Burkitt ’s lymphoma.
Source: African Health Sciences - Category: African Health Source Type: research
Conclusion: To the best of our knowledge, this is the first documented report of its kind of endemic Burkitt lymphoma involving lymphnodes generally as the primary site. High index of suspicion and early biopsy are the key in this uncommon presentation.Keywords: Burkitt lymphoma, generalized lymphadenopathy, Nigerian child.
Source: African Health Sciences - Category: African Health Source Type: research
Tumor metastasis into the central nervous system (CNS) and lymph nodes (LNs) is a major obstacle for effective therapies. Therapeutic monoclonal antibodies (mAb) have revolutionized tumor treatment; however, their efficacy for treating metastatic tumors-particularly, CNS and LN metastases-is poor due to inefficient penetration into the CNS and LNs following intravenous injection. We recently reported an effective delivery of mAb to the CNS by encapsulating the anti-CD20 mAb rituximab (RTX) within a thin shell of polymer that contains the analogs of choline and acetylcholine receptors. This encapsulated RTX, denoted as n-RT...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
ConclusionThis study shows that cardiac surgery after mediastinal radiotherapy is associated with increased short ‐ and long‐term mortality when compared to preoperative mortality risks predicted by the Euroscore II. Surgery‐related events caused all short‐term mortality cases, while malignancy‐related events were the main cause of death during the follow‐up. Mortality was higher in patients with a previous stroke and a lower estimated glomerular filtration rate.
Source: Journal of Cardiac Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: ORIGINAL ARTICLE Source Type: research
Authors: Kim S, Kim YR, Choi Y, Kim SH, Oh YS PMID: 31960642 [PubMed - as supplied by publisher]
Source: Korean Circulation Journal - Category: Cardiology Tags: Korean Circ J Source Type: research
Authors: Huang M, Tian Y, He M, Liu J, Ren L, Gong Y, Peng F, Wang Y, Ding Z, Wang J, Zhu J, Xu Y, Liu Y, Li L, Lu Y Abstract Aim: To assess the cost-effectiveness of crizotinib verses platinum-based doublet chemotherapy as the first-line treatment for Anaplastic Lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) in the real-world setting. Methods: Data from 163 advanced ALK positive NSCLC patients were collected from West China Hospital, Sichuan University (Chengdu, China). They were categorized into two groups as treated with crizotinib (n = 83) or chemotherapy (n = 80) as a fir...
Source: Journal of Comparative Effectiveness Research - Category: General Medicine Tags: J Comp Eff Res Source Type: research
Condition:   Diffuse, Large B-Cell, Lymphoma Interventions:   Drug: Polatuzumab Vedotin;   Drug: Bendamustine;   Drug: Rituximab;   Drug: Placebo Sponsor:   Hoffmann-La Roche Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Haematological Malignancy;   Leukemia, Acute;   Lymphoma;   Myeloma Multiple;   Blood Cancer;   Quality of Life Intervention:   Other: WHODAS 2.0 Questionnaire Sponsor:   University of Malaya Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Diffuse, Large B-Cell, Lymphoma Interventions:   Drug: Polatuzumab Vedotin;   Drug: Bendamustine;   Drug: Rituximab;   Drug: Placebo Sponsor:   Hoffmann-La Roche Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Angiography | Cancer & Oncology | CT Scan | Electrocardiogram | Lymphoma | Study